<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946684</url>
  </required_header>
  <id_info>
    <org_study_id>RIOTA2015</org_study_id>
    <secondary_id>2015-005682-24</secondary_id>
    <secondary_id>H-15021850</secondary_id>
    <secondary_id>HGH-2016-045_04513</secondary_id>
    <nct_id>NCT02946684</nct_id>
  </id_info>
  <brief_title>Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment</brief_title>
  <acronym>RIOT-A</acronym>
  <official_title>Reducing the Impact of Ovarian Stimulation - The RIOT Project. Study RIOT-A: The Role of Aromatase Inhibitor in Reducing the Detrimental Effects of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sven O. Skouby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holbaek Sygehus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Capital Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen University Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project seeks to determine whether estradiol suppression achieved with adjuvant
      treatment with an aromatase inhibitor improves end-follicular and midluteal phase parameters
      during IVF. 128 patients will be randomized to either placebo or active treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to investigate whether the detrimental effects of ovarian stimulation
      on outcomes in fresh embryo transfer cycles be ameliorated by co-treatment with aromatase
      inhibitors? The research questions are:

        1. Can the impact of ovarian stimulation on late follicular phase sex steroid levels (and
           hence endometrial receptivity) be mitigated by co-treatment with aromatase inhibitors
           during ovarian stimulation?

        2. Does co-treatment with aromatase inhibitors 'normalize' the endocrinology of the
           midluteal phase
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum progesterone level</measure>
    <time_frame>Assessed during stimulation treatment on day before hCG injection (throughout the study completion, up to 3 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum estradiol and testosterone levels</measure>
    <time_frame>Assessed on stimulation day 5, day of hCG administration (or the day before), day 7 and 10 after hCG administration. Assessed throughout study completion, up to 3 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P and 17-hydroxyprogesterone (17-HP) Area Under the Curve.</measure>
    <time_frame>Assessed during stimulation treatment throughout the study completion, up to 3 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicular fluid concentration of estradiol, testosterone, inhibin B and AMH levels</measure>
    <time_frame>Assessed during stimulation treatment (throughout the study completion, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total IU of Follicle Stimulating Hormone used per cycle.</measure>
    <time_frame>Assessed throughout study completion, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of follicles &gt; 12 mm</measure>
    <time_frame>Assessed in stimulated cycle on day of hCG administration or the day before (throughout the study completion), up to 3 years. Cycle length is between 21 and 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes obtained oocytes obtained.</measure>
    <time_frame>Assessed in stimulated cycle at time of oocyte pick up after follicle aspiration (throughout the study completion, up to 3 years).Cycle length is between 21 and 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of oocytes resulting in top quality day 2, day 3 embryos or day 5/6 embryos according to validated morphological criteria.</measure>
    <time_frame>Assessed at day 2-3 after oocyte pick up following stimulation (throughout study completion, up to 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oocyte fertilization rate</measure>
    <time_frame>Assessed during stimulation treatment (throughout the study completion, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and quality of embryos obtained, including rate of blastocyst formation.</measure>
    <time_frame>Assessed during stimulation treatment (throughout the study completion, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness in millimeters</measure>
    <time_frame>Assessed throughout the study completion, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>Assessed during stimulation treatment (throughout the study completion, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>Assessed 2 weeks after embryo transfer following stimulation (throughout study completion, up to 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>Pregnancy scan at gestational age week 7-8 (3-4 weeks after the positive hCG in serum). Assessed throughout study completion, up to 3 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphokinetic parameters of embryo quality as measured using a Time Lapse analysis in centers employing this technology.</measure>
    <time_frame>Assessed from time of oocyte pick-up to embryo transfer following stimulation (throughout study completion, up to 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reported side effects</measure>
    <time_frame>From start of stimulation and administration of study medication to pregnancy scan week gestational age 7-8. Assessed throughout study completion, up to 3 years.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Lactose Monohydrate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 tablets of 2,5mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Adjuvant therapy to recFSH during ovarian stimulation</description>
    <arm_group_label>Letrozole 5mg</arm_group_label>
    <other_name>Aromatase Inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Adjuvant therapy to recFSH during ovarian stimulation</description>
    <arm_group_label>Lactose Monohydrate</arm_group_label>
    <other_name>Lactose Monohydrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Indication for IVF/ICSI treatment

          -  Eligible for IVF/ICSI treatment according to local criteria

          -  Regular cycles 21-35 days (both included)

          -  Age &lt; 40

          -  AMH 8- 32 (both included)

          -  Written consent

        EXCLUSION CRITERIA

          -  Any contraindication for IVF/ICSI treatment according to local criteria

          -  Previous stimulation for IVF/ICSI with &lt; 4 oocytes obtained

          -  PCOS

          -  Undergoing IVF/ICSI for the purpose of fertility preservation

          -  Allergy towards study drug
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven O. Skouby, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unit of Reproductive Medicine, Herlev/Gentofte Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agnieszka K. Warzecha, MD</last_name>
    <phone>+45 22285871</phone>
    <email>agnieszka.warzecha@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sven O. Skouby, Professor</last_name>
    <phone>+45 44883796</phone>
    <email>sven.olaf.skouby@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Unit of Reproductive Medicine, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <state>Capital Region</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka K. Warzecha, MD</last_name>
      <phone>+45 22285871</phone>
      <email>agnieszka.warzecha@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Sven O. Skouby, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Fertility, Juliane Marie Centeret</name>
      <address>
        <city>Copenhagen</city>
        <state>Capitol Region</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Nyboe Andersen, Professor</last_name>
      <phone>+45 35454953</phone>
      <email>anders.nyboe.andersen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic of Fertility, Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <state>Capitol Region</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja B. Pinborg, Professor</last_name>
      <phone>+45 38622656</phone>
      <email>anja.bisgaard.pinborg@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic of Fertility, Holbæk Hospital</name>
      <address>
        <city>Holbæk</city>
        <state>Region Of Zealand</state>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Lis Mikkelsen, Professor</last_name>
      <phone>+45 59484270</phone>
      <email>aleg@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reproductive Medicine Unit, Zealand University Hospital</name>
      <address>
        <city>Roskilde</city>
        <state>Region Sjælland</state>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicholas S. Macklon, Professor</last_name>
      <phone>+45 47 32 10 04</phone>
      <email>nism@regionsjaelland.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Sven O. Skouby</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

